MX2022013274A - Compuestos de triazolo-pirimidina fusionados que tienen aplicacion farmaceutica util. - Google Patents

Compuestos de triazolo-pirimidina fusionados que tienen aplicacion farmaceutica util.

Info

Publication number
MX2022013274A
MX2022013274A MX2022013274A MX2022013274A MX2022013274A MX 2022013274 A MX2022013274 A MX 2022013274A MX 2022013274 A MX2022013274 A MX 2022013274A MX 2022013274 A MX2022013274 A MX 2022013274A MX 2022013274 A MX2022013274 A MX 2022013274A
Authority
MX
Mexico
Prior art keywords
pyrimidine compounds
useful pharmaceutical
pharmaceutical application
triazolo
fused
Prior art date
Application number
MX2022013274A
Other languages
English (en)
Inventor
Sergei Romanov
Robert Greenhouse
Nikolai Sepetov
Original Assignee
Nanosyn Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanosyn Inc filed Critical Nanosyn Inc
Publication of MX2022013274A publication Critical patent/MX2022013274A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)

Abstract

Un compuesto y/o una sal farmacéuticamente aceptable del mismo tiene la siguiente fórmula A: Estos compuestos pueden ser inhibidores de la cinasa PIKfyve.
MX2022013274A 2017-03-24 2019-09-23 Compuestos de triazolo-pirimidina fusionados que tienen aplicacion farmaceutica util. MX2022013274A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762601501P 2017-03-24 2017-03-24

Publications (1)

Publication Number Publication Date
MX2022013274A true MX2022013274A (es) 2022-12-13

Family

ID=63585770

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022013274A MX2022013274A (es) 2017-03-24 2019-09-23 Compuestos de triazolo-pirimidina fusionados que tienen aplicacion farmaceutica util.

Country Status (9)

Country Link
US (2) US11066410B2 (es)
EP (1) EP3600328A4 (es)
JP (2) JP7108680B2 (es)
KR (1) KR102642378B1 (es)
CN (1) CN110662544A (es)
AU (1) AU2018237598B2 (es)
CA (1) CA3056909A1 (es)
MX (1) MX2022013274A (es)
WO (1) WO2018175906A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110662544A (zh) 2017-03-24 2020-01-07 纳诺森公司 具有有用的药学应用的稠合三唑并嘧啶化合物
RS65335B1 (sr) 2018-10-05 2024-04-30 Annapurna Bio Inc Jedinjenja i kompozicije za lečenje stanja povezanih sa aktivnošću receptora apj
JP2023510874A (ja) * 2020-01-13 2023-03-15 バージ アナリティクス，インコーポレイテッド 置換ピラゾロ－ピリミジンおよびその使用
CN111494388B (zh) * 2020-05-12 2022-04-05 暨南大学 Ym201636及其药学上可接受的盐在制备抗肠道病毒感染药物中的应用
WO2021252895A2 (en) * 2020-06-11 2021-12-16 Yumanity Therapeutics, Inc. Compositions and methods for the treatment and prevention of neurological disorders
AR126013A1 (es) * 2021-06-01 2023-08-30 Verge Analytics Inc Compuestos heterocíclicos bicíclicos fusionados y usos de los mismos

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE225695C (es)
DD228811A1 (de) 1984-04-17 1985-10-23 Hydrierwerk Rodleben Veb Verfahren zur herstellung von neuen triazolopyrimidinen
DE3539386A1 (de) 1985-11-04 1987-05-14 Schering Ag N-(s-triazolo(1,5-a)pyrimidin-2-yl)-2-alkoxy-benzolsulfonamide, verfahren zur herstellung dieser verbindungen sowie diese enthaltende mittel mit herbizider und pflanzenwachstumsregulierender wirkung
JP2999808B2 (ja) 1990-08-20 2000-01-17 第一製薬株式会社 ２位置換トリアゾロピリミジン類
US5387747A (en) 1992-02-24 1995-02-07 Laboratoires Upsa Triazolopyrimidine derivatives which are angiotensin II receptor antagonists, their methods of preparation and pharmaceutical compositions in which they are present
FR2687676B1 (fr) 1992-02-24 1994-07-08 Union Pharma Scient Appl Nouveaux derives de polyazaindenes antagonistes des recepteurs a l'angiotensine ii; leurs procedes de preparation, compositions pharmaceutiques les contenant.
WO1999043678A1 (fr) * 1998-02-24 1999-09-02 Kyowa Hakko Kogyo Co., Ltd. Medicaments et prophylaxie contre la maladie de parkinson
CA2448317A1 (en) 2001-05-30 2002-12-05 Alteon Inc. Method for treating glaucoma v
CA2448306A1 (en) 2001-05-30 2002-12-05 Alteon Inc. Method for treating fibrotic diseases or other indications
US7834014B2 (en) * 2003-04-09 2010-11-16 Biogen Idec Ma Inc. A2a adenosine receptor antagonists
WO2004092171A2 (en) * 2003-04-09 2004-10-28 Biogen Idec Ma Inc. Triazolo[1,5-a]pyrimidines and pyrazolo[1,5-a]pyrimidines useful as a2a adenosin e receptor antagonists
WO2004108136A1 (en) * 2003-06-04 2004-12-16 Vernalis (Cambridge) Limited Triazolo `1 , 5-a!pyrimidines and their use in medicine
DE10356579A1 (de) * 2003-12-04 2005-07-07 Merck Patent Gmbh Aminderivate
AU2009274027A1 (en) * 2008-07-23 2010-01-28 Vertex Pharmaceuticals Incorporated Tri-cyclic pyrazolopyridine kinase inhibitors
WO2010074284A1 (ja) 2008-12-26 2010-07-01 味の素株式会社 ピラゾロピリミジン化合物
ES2580779T3 (es) 2009-02-13 2016-08-26 Bayer Intellectual Property Gmbh Pirimidinas fusionadas
EP2520659A4 (en) 2009-12-28 2013-09-25 Ajinomoto Kk SCREENING PROCESS
EP2560966B1 (en) 2010-03-30 2021-01-06 Verseon International Corporation Multisubstituted aromatic compounds as inhibitors of thrombin
CA2805015A1 (en) * 2010-07-13 2012-01-19 Stuart Ince Bicyclic pyrimidines
US10211531B2 (en) * 2014-11-05 2019-02-19 Massachusetts Institute Of Technology Compact steerable transmit antenna system
PL3215158T3 (pl) 2014-11-07 2019-11-29 Ai Therapeutics Inc Apilimod do zastosowania do leczenia raka nerki
US10729694B2 (en) * 2015-01-23 2020-08-04 AI Therapeutics, Inc. Anti-viral compositions containing PIKfyve inhibitors and use thereof
CN105963300B (zh) 2015-03-13 2019-06-11 中国人民解放军军事医学科学院放射与辐射医学研究所 PIKfyve抑制剂抗辐射损伤的用途
WO2017040971A1 (en) 2015-09-03 2017-03-09 Biomarin Pharmaceutical Inc. Methods of using inhibitors of pikfyve for the treatment of lysosomal storage disorders and neurodegenerative diseases
US20180036420A1 (en) 2016-08-03 2018-02-08 Lam Therapeutics, Inc. Methods for enhancing the delivery of molecules across the blood brain barrier
US20180050041A1 (en) 2016-08-19 2018-02-22 Lam Therapeutics, Inc. Compositions and Methods for Treating Niemann Pick C Disease
AU2017316475A1 (en) 2016-08-25 2019-03-07 AI Therapeutics, Inc. Compositions comprising PIKfyve inhibitors and methods related to inhibition of rank signaling
GB201616237D0 (en) 2016-09-23 2016-11-09 Univ Oslo Hf Modulation of function of immune effector cells
WO2018138106A1 (en) 2017-01-27 2018-08-02 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of heart failure
CN110662544A (zh) 2017-03-24 2020-01-07 纳诺森公司 具有有用的药学应用的稠合三唑并嘧啶化合物
TWI820209B (zh) * 2018-09-12 2023-11-01 大陸商迪哲（江蘇）醫藥股份有限公司 三唑并－嘧啶化合物及其用途
FR3095755A1 (fr) 2019-05-10 2020-11-13 Balmes Transplantation Nouveaux médicaments cytoprotecteurs
AR119934A1 (es) 2019-09-12 2022-01-19 Ai Therapeutics Inc Inhibidores de pikfyve para terapia contra el cáncer
EP4058017A4 (en) 2019-11-13 2023-12-13 The Regents of the University of California DRUG FORMULATIONS AND METHODS OF TREATMENT OF METABOLIC DISORDERS

Also Published As

Publication number Publication date
JP7108680B2 (ja) 2022-07-28
AU2018237598A1 (en) 2019-10-10
JP2022160463A (ja) 2022-10-19
US20200079780A1 (en) 2020-03-12
US11066410B2 (en) 2021-07-20
US11987583B2 (en) 2024-05-21
WO2018175906A1 (en) 2018-09-27
KR20200007781A (ko) 2020-01-22
US20210323969A1 (en) 2021-10-21
AU2018237598B2 (en) 2023-12-14
EP3600328A1 (en) 2020-02-05
CA3056909A1 (en) 2018-09-27
KR102642378B1 (ko) 2024-02-28
EP3600328A4 (en) 2021-01-06
JP2020511549A (ja) 2020-04-16
CN110662544A (zh) 2020-01-07

Similar Documents

Publication Publication Date Title
MX2022013274A (es) Compuestos de triazolo-pirimidina fusionados que tienen aplicacion farmaceutica util.
SA520411990B1 (ar) مركبات مفيدة لتثبيط إنزيم كيناز 7 المعتمد على السيكلين
EP3752491A4 (en) HETEROCYCLIC COMPOUNDS USED AS KINASE INHIBITORS
PH12017501523A1 (en) Selective bace1 inhibitors
MY180083A (en) Tetrahydropyrrolothiazine compounds
PH12016500467A1 (en) Aminoheteroarlyl benzamides as kinase inhibitors
GEP20207111B (en) Heteroaryl compounds for kinase inhibition
WO2017075629A3 (en) Wee 1 kinase inhibitors and methods of making and using the same
MA39749A (fr) Dérivés de pipéridine-dione
SG11202011513RA (en) Heterocyclic compounds as kinase inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof
EP3672973A4 (en) HETEROCYCLIC COMPOUNDS USED AS KINASE INHIBITORS, COMPOSITIONS INCLUDING THE HETEROCYCLIC COMPOUND, AND METHODS OF USE THEREOF
PH12019501022A1 (en) Pyrazolopyrimidine compounds and methods of use thereof
MA40059A (fr) Inhibiteurs de la phosphatidylinositol 3-kinase
HK1244704A1 (zh) 一種含有jak激酶抑制劑或其可藥用鹽的藥物組合物
EP3480198A4 (en) NEW COMPOUND OR ITS PHARMACEUTICALLY ACCEPTED SALT
PH12016502246B1 (en) Carboxamide derivatives
EP3666770A4 (en) NEW HETEROCYCLIC COMPOUNDS AS CDK8 / 19 INHIBITORS
MX2018014813A (es) Composiciones antibacterianas.
PH12019500875A1 (en) Pyridone compound as c-met inhibitor
PH12019500370A1 (en) Triazolopyrazinone derivative useful as a human pde1 inhibitor
MX2016006667A (es) Derivados de pirrolo-pirrolona y su uso como inhibidores.
MX2016013561A (es) Activadores de herg policiclicos.
MX2018002193A (es) Metodo de uso de quinoxalinilo-piperazinamida.
WO2016003827A3 (en) Fused cycloalkyl-pyrimidine compounds and uses thereof